1-3 of 3
Xingyu Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4664.
https://doi.org/10.1158/1078-0432.CCR-21-2433
Published: 15 August 2021
View article titled, Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Journal Articles

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3190–3200.
https://doi.org/10.1158/1078-0432.CCR-20-3363
Published: 01 June 2021
View article titled, Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial

Terry A. Day, Keisuke Shirai, Paul E. O'Brien, Maria Gisele Matheus, Kristina Godwin, Amit J. Sood, Anvesh Kompelli, Julie A. Vick, Daniel Martin, Lynn Vitale-Cross, Juan Luis Callejas-Varela, Zhiyong Wang, Xingyu Wu, Olivier Harismendy, Alfredo A. Molinolo, Scott M. Lippman, Carter Van Waes, Eva Szabo, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1156–1164.
https://doi.org/10.1158/1078-0432.CCR-18-2024
Published: 15 February 2019
View article titled, Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Open the PDF for Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial in another window
Includes: Supplementary data